Bone mineral density response to raloxifene monotherapy or in combination with alfacalcidol in postmenopausal Japanese women with osteoporosis or osteopenia.

Trial Profile

Bone mineral density response to raloxifene monotherapy or in combination with alfacalcidol in postmenopausal Japanese women with osteoporosis or osteopenia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 May 2012

At a glance

  • Drugs Raloxifene (Primary) ; Alfacalcidol
  • Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2011 2 year results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top